The most important thing on this ingredient list is what is not on it. The lash serums that made the category famous in the 2010s worked because they contained prostaglandin analogues, cousins of the glaucoma drug bimatoprost, which act on the follicle's growth cycle with drug-level potency and produced dramatic lengthening along with darkened lids, permanently browned irises in some users, and a hollowing of the eye socket as orbital fat thinned. The Ordinary's serum, launched in 2020, contains none of that. Its list is water, glycols, four cosmetic peptides, caffeine, panthenol, a few extracts borrowed from the brand's hair density serum, conditioning proteins and preservatives, and everything that follows from that choice, the safety and the modesty alike, is the review.
The peptides are the cosmetic industry's replacement for the prostaglandins, and they come with the industry's kind of evidence. Myristoyl pentapeptide-17 is fourth on the list, straight after the humectants, which puts it at or near its supplier's recommended dose; the supplier sells it as a stimulator of keratin genes in the lash follicle on the strength of a study reporting longer-looking lashes after a few weeks, and nobody has replicated it. Biotinoyl tripeptide-1, oligopeptide-2 and acetyl tetrapeptide-3 follow at fifth to seventh, hair-cycle peptides from the scalp-serum world with supplier data of the same kind. Caffeine at eighth has laboratory evidence in cultured hair follicles for countering testosterone's suppression of growth, which is real if not lash-specific, and panthenol at ninth conditions the shaft. Larch, red clover and green tea extracts, the botanical halves of the Redensyl and Capixyl complexes, sit further down. One small independent trial exists for the category, a 2024 open clinical study of a peptide-and-glycosaminoglycan lash enhancer reporting improved lash appearance over weeks, which is the closest thing to outside support and is not a study of this product. The honest reading is a formula assembled from the best-marketed cosmetic lash ingredients at sensible levels, with a rationale and no proof.
What the serum reliably does is not what the peptides are for. Glycoproteins, arginine, glycine and panthenol coat and soften the lash shaft, and within a week or two lashes are glossier, more flexible and less brittle, which is the effect most users notice first and read as fuller. That is a conditioning result, not a growth one, and it is genuine. Length and density, if they change, take a lash cycle of six to twelve weeks to show, and six years of divided reviews say what the evidence predicts: a good share of users report longer or thicker lashes at two or three months, a good share report only the gloss, and almost nobody reports the dramatic change a prostaglandin serum gives. Brows, which cycle slower, follow the same pattern more slowly. Anyone who has over-plucked brows for years should also know that follicles closed by long-term traction do not reopen for a peptide, and that the serum's realistic brow contribution is darker-looking, better-conditioned hairs rather than new ones.
The safety side is where leaving out the prostaglandin pays. There is no lid darkening, no iris risk, no fat loss, no redness for most users, and the serum is fragrance-free, alcohol-free, oil-free and vegan; the only ingredients of note are sodium metabisulfite, for the sulfite-sensitive, and benzoic acid in the preservative system, and the only reliable complaint is a brief sting when the gel gets into the eye, which is why the instructions say one stroke along the base of the upper lashes and nothing on the lower ones. It is water-based, so it does not dissolve extension adhesive, and it goes on before eye cream rather than over it.
Under fifteen dollars for 5 ml sounds small until the dose is counted: a single stroke a night along the upper lash line and through the brows makes the tube last two to three months, a full lash cycle, which is exactly the length of trial the peptides need to be judged. Prostaglandin-free peptide lash serums from prestige brands cost fifty to a hundred dollars for the same or smaller volumes with the same supplier evidence, and the prescription drug costs more still and carries its risks. The Ordinary's version has been in the range since 2020 with a review history far larger than any single count captured this session, and the brand publishes no trial of it, which for a cosmetic lash serum is the industry norm rather than a mark against it.
For anyone who wants their lashes to look healthier, softer and glossier without risking their eyelids, and who is content with a modest, uncertain chance of length on top, this is the sensible, cheap, well-made choice and the one a cautious ophthalmologist would prefer. For anyone who wants the transformation the notorious serums delivered, the absence on this label is exactly the point, and it cuts both ways.
